MEET THE GUEST EDITOR

John McCarter is a Principal Scientist in Lead Discovery at Amgen where he leads a group focusing on the discovery and development of small molecule therapeutics for enzyme and cellular targets. Prior to joining Amgen in 2000, John was a Senior Scientist and Project Leader at Axys Pharmaceuticals where he contributed to the cathepsin K program leading to the clinical development (partnered with Merck) of inhibitors of this enzyme for the treatment of osteoporosis. He was a Medical Research Council of Canada postdoctoral fellow with Prof. Jack Kirsch at the University of California at Berkeley and earned his Ph.D. in Chemistry on mechanisms and inhibitors of glycosidases at the University of British Columbia.